Diabetes: lipid-lowering therapies for primary prevention of CVD (T2DM and 10% risk)
This indicator covers the percentage of patients with a diagnosis of type 2 diabetes and a recorded cardiovascular disease risk assessment score of 10% or more (without moderate or severe frailty), who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.
Last reviewed: 27 November 2024
This indicator updates and replaces NICE indicator IND182.
Next review: 30 November 2027
This indicator will be reviewed using the assessment criteria in appendix B of the NICE indicators process guide when it reaches its review date or the underlying guidance is updated.
How to use NICE indicators and how we develop them
Indicators can be used in a number of different settings to support high quality care. These include:
- identifying where improvements are needed
- setting priorities for quality improvement and support
- creating local performance dashboards
- benchmarking performance against national data
- supporting local quality improvement schemes
- showing progress that local health systems are making on outcomes.
Find out how to use indicators and how we develop them.